195 related articles for article (PubMed ID: 12542524)
1. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Paul CF; Ho VC; McGeown C; Christophers E; Schmidtmann B; Guillaume JC; Lamarque V; Dubertret L
J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
Katz KA; Marcil I; Stern RS
J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
[TBL] [Abstract][Full Text] [Related]
3. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.
Marcil I; Stern RS
Lancet; 2001 Sep; 358(9287):1042-5. PubMed ID: 11589933
[TBL] [Abstract][Full Text] [Related]
4. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
5. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies.
Naldi L
Clin Dermatol; 2010; 28(1):88-92. PubMed ID: 20082957
[TBL] [Abstract][Full Text] [Related]
6. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
7. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.
Stern RS; Nichols KT; Väkevä LH
N Engl J Med; 1997 Apr; 336(15):1041-5. PubMed ID: 9091799
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis, its treatment, and cancer in a cohort of Finnish patients.
Hannuksela-Svahn A; Pukkala E; Läärä E; Poikolainen K; Karvonen J
J Invest Dermatol; 2000 Mar; 114(3):587-90. PubMed ID: 10692122
[TBL] [Abstract][Full Text] [Related]
9. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.
Stern RS;
J Am Acad Dermatol; 2012 Apr; 66(4):553-62. PubMed ID: 22264671
[TBL] [Abstract][Full Text] [Related]
10. Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination.
Aydin F; Yuksel EP; Senturk N; Canturk T; Turanli AY
Cutan Ocul Toxicol; 2014 Sep; 33(3):181-3. PubMed ID: 23944659
[TBL] [Abstract][Full Text] [Related]
11. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study.
Nijsten TE; Stern RS
J Invest Dermatol; 2003 Aug; 121(2):252-8. PubMed ID: 12880415
[TBL] [Abstract][Full Text] [Related]
12. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.
Seidl H; Kreimer-Erlacher H; Bäck B; Soyer HP; Höfler G; Kerl H; Wolf P
J Invest Dermatol; 2001 Aug; 117(2):365-70. PubMed ID: 11511317
[TBL] [Abstract][Full Text] [Related]
13. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
Behnam SM; Behnam SE; Koo JY
J Drugs Dermatol; 2005; 4(2):189-94. PubMed ID: 15776776
[TBL] [Abstract][Full Text] [Related]
14. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients.
Lim JL; Stern RS
J Invest Dermatol; 2005 Mar; 124(3):505-13. PubMed ID: 15737190
[TBL] [Abstract][Full Text] [Related]
15. Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan.
Lee MS; Chang CH; Lin RY; Lai MS
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):133-40. PubMed ID: 26521982
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine.
Väkevä L; Reitamo S; Pukkala E; Sarna S; Ranki A
Acta Derm Venereol; 2008; 88(2):117-20. PubMed ID: 18311436
[TBL] [Abstract][Full Text] [Related]
17. The risk of melanoma in association with long-term exposure to PUVA.
Stern RS;
J Am Acad Dermatol; 2001 May; 44(5):755-61. PubMed ID: 11312420
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.
Di Lernia V; Ricci C
J Dermatolog Treat; 2011 Aug; 22(4):229-32. PubMed ID: 20666674
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
Aydin F; Canturk T; Senturk N; Turanli AY
Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
[TBL] [Abstract][Full Text] [Related]
20. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
Br J Dermatol; 2014 Feb; 170(2):366-73. PubMed ID: 24251402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
